The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.

He stated that he regularly used insulin three times a week to help increase his muscle bulk, but the previous day he had used a different type of insulin (fast acting) from usual. He also admitted to ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

In the future, patients may only need to inject this smart insulin once a week, instead of several times a day. A lot of ...

Trials including commercially available formulations of insulin detemir or insulin glargine were compared with NPH. Pertinent English-language clinical trials published between 2000 and 2006 were ...

Type one diabetics currently must inject themselves with synthetic insulin up to ten times daily ... has been launched to find a ultra-fast acting variant. Dr Tim Heise, the vice-chair of the ...

Mariposa California's original daily updated online newspaper is the premier site for news and information on Yosemite, ...

The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) ...

Opens in a new tab or window The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.